Abstract-Metabolic abnormalities develop in various chronic diseases and lead to progressive catabolism with decrements in the skeletal musculature that result in muscle atrophy. We investigated pathways of skeletal muscle proteolysis using an experimental model of chronic left-ventricular dysfunction. Skeletal muscle atrophy developed in wild-type mice 12 weeks following myocardial infarction accompanied by an increase in total protein ubiquitination and enhanced proteasome activity, activation of Foxo transcription factors, and robust induction of the ubiquitin-protein ligase atrogin-1/MAFbx. Further studies identified skeletal muscle myosin as a specific target of ubiquitin-mediated degradation in muscle atrophy. In contrast, transgenic overexpression of a local isoform of insulin-like growth factor-1 prevented muscle atrophy and increased proteasome activity, inhibited skeletal muscle activation primarily of Foxo4, and blocked the expression of atrogin-1/MAFbx. These results suggest that skeletal muscle atrophy occurs through increased activity of the ubiquitin-proteasome pathway. The inhibition of muscle atrophy by local insulin-like growth factor-1 provides a promising therapeutic avenue for the prevention of skeletal muscle wasting in chronic heart failure and potentially other chronic diseases associated with skeletal muscle atrophy. 
P rogressive metabolic abnormalities leading to a catabolic state have been observed in various chronic diseases, including heart and renal failure, AIDS, and cancer. [1] [2] [3] A common characteristic is the development of specific myopathic changes and a loss of lean muscle mass. 4 In chronic heart failure, alterations in multiple anabolic and catabolic systems result in progressive catabolism leading to cardiac cachexia in advanced stages of the disease. 1, 5 Early stages of chronic heart failure-related muscle atrophy correlate with reduced expression of insulin-like growth factor (IGF)-1, 6 activation of systemic, 5 and local 6 markers of inflammation, as well as increased oxidative stress. 7 However, the specific mechanisms underlying skeletal muscle dysfunction and progressive muscle atrophy in chronic heart failure are still incompletely understood.
Catabolic loss of muscle protein occurs primarily through enhanced protein breakdown mediated by the ubiquitinproteasome pathway. 8 The critical regulators of protein ubiquitination are ubiquitin-protein ligases E3 that catalyze the transfer of activated ubiquitin from an ubiquitin-conjugating enzyme (E2). Individual ubiquitin ligases selectively target specific proteins for ubiquitination and exhibit tissue-specific and inducible expression patterns. 9, 10 Proteins marked by chains of ubiquitin are rapidly degraded through the 26S proteasome in a ATP-dependent process that yields peptides and intact ubiquitin. 8 The crucial role of the ubiquitinproteasome pathway has been demonstrated in several models of muscle atrophy that include starvation, uremia, denervation, sepsis, and diabetes mellitus. 9 -12 The present study was undertaken to investigate whether activation of the ubiquitin-proteasome pathway contributes to muscle atrophy in the syndrome of chronic heart failure. Because progressive muscle atrophy in advanced stages of chronic heart failure correlates with low serum levels and reduced local expression of IGF-1, 6, 13 we hypothesized that expression an MLC/mIgf-1 transgene encoding a locally acting isoform of IGF-1 normally induced in response to muscle damage, 14 could prevent the development of heart failure-associated muscle atrophy and concomitant activation of the proteasome.
Here we show that muscle activation of the ubiquitinproteasome pathway in the setting of chronic left-ventricular dysfunction (CLVD) is accompanied by selective induction of the muscle-specific ubiquitin ligase atrogin-1/MAFbx (Muscle Atrophy F-box), presumably through the activation of Foxo transcription factors in the skeletal muscle. Trans-genic supplementation of the mIgf-1 isoform prevents muscle atrophy and activation of the proteasome. Further, overexpression of mIgf-1 specifically inhibits activation of Foxo4, the most abundant of these factors in skeletal muscle, and blocks expression of atrogin-1/MAFbx. These studies establish a role for ubiquitin-mediated proteolytic degradation in muscle atrophy accompanying CLVD and highlight the potential therapeutic value of supplementing the local mIgf-1 isoform in the treatment of progressive muscle wasting accompanying heart failure.
Materials and Methods

Animal Model
Myocardial infarction was induced under anesthesia in 8-to 12-week-old male FVB mice (wild-type [WT] ) and in an FVB transgenic mouse line (MLC/mIgf-1) with skeletal muscle-restricted expression of the Exon1-Ea isoform of the rat Igf-1 gene. 14 Progressive cardiac dysfunction was induced by ligation of the left coronary artery, whereas sham-operated animals underwent the same procedure without ligation of the coronary artery. All mice underwent echocardiography after 2 and 12 weeks and were euthanized after 12 weeks by injection of pentobarbital. The investigation conformed to the NIH Guide for the Care and Use of Laboratory Animals (Publication No. 85-23, revised 1996) and was approved by the Harvard Medical School Standing Committee on Animals.
Histology
Organs were removed, fixed in 4% paraformaldehyde, and embedded in paraffin for further histological analysis. Tissue samples were cut in 5-m thick sections and stained using hematoxylin and eosin, as well as sirius red. Morphological analysis of muscle fiber cross-sectional area was performed on tissue scans using ImagePro software (ImagePro Plus 4.5, Media Cybernetics).
Detection of Apoptosis
The rate of apoptosis was assessed by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling. Further, immunohistochemistry was performed using antibodies against cleaved caspase-3 (Cell Signaling). Using light microscopy, the percentage of dark brown nuclei was analyzed and expressed as percentage of total nuclei as described previously. 15 
Vascular Density
Capillaries were stained immunohistochemically using antibodies directed against lectin (Molecular Probes). Capillary density was measured by counting random fields on skeletal muscle sections using light microscopy as described previously. 15 Total capillary number was corrected for muscle fibers and expressed as capillaries per muscle fiber ratio.
Cell Culture
SOL8 cells (American Type Culture Collection) were cultured in DMEM containing 20% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin. Cells were incubated with tumor necrosis factor-␣ (20 ng/mL), interleukin-1␤ (50 ng/mL), IGF-1 (10 ng/mL), and dexamethasone (Dexa; 10 ng/mL). Further, the pharmacological inhibitors Wortmannin (100 nmol/L; Sigma), U126 (10 mol/L; Calbiochem), PD169316 (100 nmol/L; Calbiochem), and rapamycin (20 ng/mL; Cell Signaling) were used in the present study.
Real-Time Polymerase Chain Reaction
Total RNA (100 ng) was assessed by real-time polymerase chain reaction (PCR) (LightCycler; Roche) using primers for atrogin-1/ MAFbx (sense: 5Ј-GAC TGG ACT TCT CGA CTG CC-3Ј; antisense: 5Ј-TCA GCC TCT GCA TGA TGT TC-3Ј) and ␤-tubulin (sense: 5Ј-CTG GGC TAA AGG CCA C-3Ј; antisense: 5Ј-AGA CAC TTT GGG CGA G-3Ј). The expression was normalized to expression levels of ␤-tubulin.
Western Blot Analysis
Protein levels were analyzed by Western blot analysis using specific monoclonal antibodies for the detection of myosin heavy chain (MF20; Developmental Studies Hybridoma Bank) or ubiquitin (P4D1; Santa Cruz Biotechnology). Polyclonal antibodies against phosphorylated Akt, total Akt, phosphorylated Foxo1, -3, and -4, total Foxo, phosphorylated mammalian target of rapamycin (mTOR), p70 s6k , total mTOR, phosphorylated p38 mitogen-activated protein kinase (MAPK), total p38 MAPK, p42/44 MAPK, and extracellular signal regulated kinase 1/2 were from Cell Signaling. After incubation with horseradish peroxidase-conjugated secondary antibody, specific bands were visualized by enzymatic chemiluminescence (Perkin Elmer).
Immunoprecipitation
Thirty microliters of protein A Sepharose beads were incubated with 1 g of anti-ubiquitin antibody. Total protein (300 g) from the soluble fraction of the muscle lysates were incubated with antibody bead complexes for 2 hours rotating at 4°C. Beads were centrifuged and washed 3 times with 0.5 mL of lysis buffer and 1 time with 0.5 mL of ice-cold PBS. The beads were resuspended in SDS sample buffer, incubated at 95°C for five minutes, centrifuged, and the supernatant electrophoresed through a SDS-PAGE system. After transfer to a polyvinylidene difluoride membrane, further immunoblotting was performed.
Proteasome Activity
Protein lysates were incubated at 37°C with proteasome assay buffer containing 10 mol/mL SLLVT-7-amino-4-methylocoumarin (Calbiochem) as substrate for the chymotrypsin-like activity of the proteasome. Specificity was tested by using MG132 (10 mol/L; Sigma) and lactacystin (20 mol/L; Sigma) to inhibit 20S proteasome activity. Fluorescence of free 7-amino-4-methylocoumarin as a measure of proteasome activity was assessed in intervals over 60 minutes on a temperature-controlled fluorescence reader (Perkin Elmer).
Statistical Analysis
All experiments were performed at least 3 times, and data are expressed as meanϮSEM. Data were analyzed by Student t test for comparisons of 2 data groups. One-way ANOVA with Tukey post hoc analysis was used for the analysis of data sets of more than 2 groups. A probability value of PϽ0.05 was considered statistically significant. The statistical analysis was performed using the GraphPad InStat software package (Version 3.05 for Windows 95/NT).
Results
Assessment of an Animal Model of CLVD
Thirty-nine WT and 34 MLC/mIgf-1 transgenic mice were included in the study (online Table available Table) . Heart weight corrected for body weight was comparable between the 2 groups both at baseline and following myocardial infarction, indicating no specific cardiac effects in animals with skeletal muscle-restricted overexpression of mIgf-1 compared with WT animals.
Skeletal Muscle Atrophy and Activation of the Ubiquitin-Proteasome Pathway in CLVD
Assessment of skeletal muscle revealed a reduction in muscle fiber cross-sectional area in WT animals with CLVD ( Figure  1A and 1B). This reduction was paralleled by a decrease in isolated muscle weight (online Table) . Anti-ubiquitin immunoblotting revealed an increase in ubiquitinated substrates in soluble fractions of atrophying muscles ( Figure 1C) . The activity of the 20S proteasome was measured by assessment of the chymotrypsin-like proteolytic activity. WT animals with CLVD and muscle atrophy displayed an increase in 20S proteasome activity in skeletal muscle by 40% (PϽ0.05 versus controls) ( Figure 1D ). No increase in the rate of apoptosis in skeletal muscle myocytes was detected in animals with left-ventricular dysfunction. However, an increased rate of vascular apoptosis (199Ϯ77% of sham-operated animals; PϽ0.05) was found in muscle specimens of WT animals following myocardial infarction. Notably, signs of vascular rarefaction were found in skeletal muscle of animals with CLVD following myocardial infarction. Vascular density (capillary to myocyte ratio) decreased in skeletal muscle of animals with CLVD by 24% (PϽ0.05 versus sham surgery).
Transgenic Overexpression of mIgf-1 Prevents Activation of the Ubiquitin-Proteasome Pathway and Muscle Atrophy in CLVD
Next, we assessed skeletal muscle activation of the proteolytic ubiquitin-proteasome pathway in MLC/mIgf-1 transgenic animals. Muscle fiber cross-sectional area of MLC/ mIgf-1 mice was increased at baseline because of the anabolic function of the locally overexpressed mIgf-1 isoform. 16 In contrast to WT animals, MLC/mIgf-1 mice with CLVD experienced no reduction of muscle fiber cross-sectional area ( Figure 1A and 1B) . Further, transgenic overexpression of mIgf-1 prevented the increase in total muscle protein ubiquitination following myocardial infarction ( Figure 1B) . Finally, the increase in proteasome activity was prevented in skeletal muscle of MLC/mIgf-1 transgenic mice with CLVD ( Figure 1C) . In contrast to WT animals with CLVD, MLC/ mIgf-1 mice with CLVD did not show changes in the rate of vascular apoptosis, indicating that local IGF-1 might regulate vascular apoptosis in skeletal muscle (131Ϯ31% of shamoperated animals; PϭNS). Overexpression of mIgf-1 tended to increase capillary density; however, this increase did not reach statistical significance (ϩ13% versus WT; PϭNS). Overexpression of mIgf-1 reduced but did not completely block the loss in capillary density in animals with CLVD (Ϫ24Ϯ8% in WT versus Ϫ15Ϯ6% in mIgf-1 animals; Pϭ0.08).
IGF-1 Blocks Expression of atrogin-1/MAFbxMediated Ubiquitination in Muscle Cell Cultures
To identify potential structural targets of the ubiquitinproteasome pathway in muscle atrophy, we challenged SOL8 myogenic cell cultures with dexamethasone and cytokines as well as starvation and analyzed protein ubiquitination status with immunoprecipitation, which effectively isolates ubiquitinated protein complexes as detected by anti-ubiquitin immunoblotting (Figure 2A) . Whereas Western blot analysis showed no differences in overall total myosin heavy-chain (MyHC) protein, 24-hour dexamethasone treatment induced a robust increase in MyHC ubiquitination ( Figure 2B ), which was also seen after serum withdrawal and tumor necrosis factor-␣ and interleukin-1␤ (data not shown). Thus, myosin ubiquitination may contribute to muscle cell atrophy.
E3-ligases are ubiquitin-protein-conjugating enzymes with a crucial role in the molecular cascade of protein ubiquitination, which marks them for rapid proteolytic degradation. 9, 10 Induction of the E3-ligase atrogin-1/MAFbx in the setting of muscle atrophy was first confirmed in SOL8 cells starved by serum withdrawal for 72 hours. This effect was reduced by stimulation with 20% serum for 3 hours and completely normalized by addition of recombinant IGF-1 to the media for 3 hours ( Figure 2C) .
Analysis of the underlying pathways mediating the suppressive effects of IGF-1 on atrogin-1/MAFbx expression in SOL8 cells revealed robust activation of Akt, mTOR, and p70 s6k ( Figure 2D) , which all have been demonstrated to contribute to the prohypertrophic and antiatrophic effects of IGF-1 in skeletal muscle. 14,17-21 Pharmacological inhibition of p42/44 MAPK and p38 MAPK did not affect suppression of atrogin-1/MAFbx expression by IGF-1. In contrast, the effects of IGF-1 on the expression of atrogin-1/MAFbx in SOL8 cultures were completely blocked by phosphatidylinositol 3 (PI3) kinase inhibition and reduced by mTOR inhibition ( Figure 2E ).
Transgenic Expression of mIGF-1 Blocks Polyubiquitination of MyHC in CLVD-Induced Muscle Atrophy
To determine whether MyHC was a target of ubiquitinmediated proteolytic degradation in vivo, we performed similar analyses on mouse skeletal muscle and found an increased fraction of ubiquitinated MyHC in WT animals with CLVD ( Figure 3A) . Expression of the MLC/mIgf-1 transgene blocked the increase in MyHC ubiquitination in skeletal muscle of animals with chronic CLVD. We also analyzed expression of atrogin-1/MAFbx in several muscle groups of mice with CLVD ( Figure 3B ). Quantitative real-time PCR revealed that transcripts of atrogin-1/MAFbx were strongly induced in atrophying muscles of animals with CLVD (3.48Ϯ1.38 versus 1.21Ϯ0.32 arbitrary units; PϽ0.01 versus WT sham). In MLC/mIgf-1 transgenic muscle, expression of atrogin-1/MAFbx remained at basal levels following the development of CLVD ( Figure 3C ). These results support a model wherein mIgf-1 blocks the degradation of myosin in CLVD by repressing the induction of atrogin-1/MAFbx expression.
Transgenic Overexpression of mIgf-1 Selectively Inhibits Activation of Specific Foxo Transcription Factors in Muscles of Mice With CLVD
To delineate the signals responsible for the prevention of CLVD-induced muscle atrophy and atrogin-1/MAFbx activation in MLC/mIgf-1 transgenic muscle, we monitored the activation status of the Akt/mTOR/p70 s6k pathway in the setting of chronic heart failure ( Figure 4A and B) . Phosphorylated Akt (which represents the active form of the kinase) was reduced in atrophied skeletal muscle of WT mice with CLVD (Ͼ50% reduction versus sham surgery; PϽ0.05). CLVD did not change the activity of mTOR or p70 s6k , suggesting that the mTOR/p70 s6k pathway is not implicated in heart failure-induced muscle atrophy.
In contrast, no reduction of Akt activity was observed in the muscles of MLC/mIgf-1 transgenic mice with CLVD. Increased levels of phosphorylated mTOR and p70 s6k in MLC/mIgf-1 transgenic muscle were also maintained after induction of CLVD, implicating this pathway in the maintenance of muscle mass and integrity in response to MLC/ mIgf-1 overexpression.
The Akt/mTOR/ p70 s6k pathway has been implicated in the restriction of Foxo transcription factor activity that, in turn, controls the atrogin-1/MAFbx gene. 22 Foxo transcription factors are activated by dephosphorylation, and repression of Akt activity in the muscles of WT mice with CLVD was accompanied by selective activation of Foxo4 by dephosphorylation (Ͼ70% reduction versus sham surgery; PϽ0.05) without significant changes in the other 2 Foxo transcription factors 1 and 3 ( Figure 4A and 4B) . Notably, activation of Foxo4 was blocked by mIgf-1 overexpression, as documented by increased Foxo4 phosphorylation ( Figure 4A and 4B) .
Taken together, these results implicate that skeletal muscle atrophy in the setting of CLVD is accompanied by reduced Akt activation, leading to activation of Foxo transcription factors without significantly affecting the mTOR and p70 s6k pathway. Overexpression of mIgf-1 activates both the PI3K/ Akt/Foxo pathway as well as the mTOR/p70 s6k pathway, indicating that supplemental mIgf-1 expression might inhibit muscle atrophy through several intracellular signaling events.
Discussion
In this study, we used an animal model of CLVD to implicate the ubiquitin-proteasome pathway in skeletal muscle atrophy accompanying heart disease and to explore potential therapeutic avenues for its prevention. Induction of the ubiquitinproteasome pathway in atrophying skeletal muscle was accompanied by Foxo activation and expression of the atrophyrelated ubiquitin-protein ligase atrogin-1/MAFbx. These changes are prevented by transgenic overexpression of mIgf-1.
CLVD results in profound metabolic changes that affect various endocrine systems and leads to an imbalance of catabolic over anabolic function. 5 Patients with chronic heart failure exhibit elevated levels of proinflammatory cytokines, 1, 5 an imbalance between catabolic and anabolic steroids, 5 insulin resistance, 23 and oxidative stress. 24 chronic heart failure induces structural skeletal muscle abnormalities that include mitochondria, 25 changes in enzyme distribution from slow toward fast glycolytic isoforms, 26 a shift from slow twitch to fast twitch fibers, 25 and local cytokine expression, 6 as well as a catabolic loss of muscle bulk in advanced stages of the disease. 1, 5, 13 Intriguingly, a reduced skeletal muscle expression of IGF-1 has been demonstrated in patients with chronic heart failure, 13 as well as in animal models of CLVD. 6, 27, 28 These findings formed the rationale for the present experimental study.
Enhanced protein breakdown, a central event in catabolic loss of muscle proteins, is primarily mediated by the ubiquitin-proteasome pathway. 8 In animal models of starvation, 9 diabetes, 11 and sepsis, 12 this pathway has been identified as the central mediator of protein degradation. Indeed, ubiquitinated conjugates and genes that encode components of the ubiquitin-proteasome pathway increase during atrophy, 9,29 whereas inhibition of the 26S proteasome prevents progression of muscle atrophy. 30 Several structural muscle proteins (eg, myosin and troponin) are subject to ATP-dependent degradation through the 26S proteasome. 31, 32 The present study identifies increased activity of the ubiquitin-proteasome pathway as a mechanism contributing to skeletal muscle atrophy in CLVD caused by enhanced MyHC polyubiquitination. This finding is consistent with previous reports demonstrating degradation of myosin through the ubiquitin-proteasome pathway in other settings, 31 as well as increased polyubiquitination of MyHC in dilated cardiomyopathy 33 and in cancer cachexia. 32 However, the molecular and structural characteristics underlying this mechanism are still unclear. The biochemical measurements performed in this study used total muscle tissue lysates. Whereas myocytes are the highly predominant portion of muscle tissue, other cells and tissues, such as extracellular matrix and vasculature, constitute normal skeletal muscle. Therefore, pathological abnormalities in those compartments might also have contributed to the observed functional derangements of skeletal muscle.
Ubiquitin-protein ligases play a crucial role in mediating ubiquitination of specific substrates. Elevated levels of the ubiquitin-protein ligase atrogin-1/MAFbx in skeletal muscle of mice with CLVD correlates well with other studies documenting increased atrogin-1/MAFbx expression in muscle atrophy incurred by immobilization, denervation, hindlimb suspension, and starvation. 9, 10 The induction of atrogin-1/MAFbx expression before muscle weight loss suggests its involvement in development and progression of muscle protein loss. 9 In support of this possibility, overexpression of atrogin-1/MAFbx induces atrophy in vitro, whereas muscle atrophy was prevented in animals with targeted deletion of atrogin-1/MAFbx. 10 Maintenance of Akt/mTOR/p70 s6k signaling is 1 potential mechanism whereby expression of the MLC/mIgf-1 transgene abrogates muscle atrophy and breakdown of muscle structural proteins. Indeed, intramuscular administration of IGF-1 protein induces Akt phosphorylation, inhibits denervation-induced muscle loss, and blocks the increased expression of MAFbx and MuRF1. 20 Although no direct inhibitors of Akt signaling have been identified in atrophying skeletal muscle to date, its repression in various stages of muscle atrophy, 22 as well as anticatabolic effects of constitutively active Akt, 20 implicate this pathway in maintenance of muscle mass. Intriguingly, exogenous administration of growth hormone to rats with CLVD counters the decline in skeletal muscle function, structure, and morphology. 34 Activation of the Akt pathway also occurs downstream of the ␤ 2 -adrenergic receptor through the second messenger cAMP. In chronic heart failure, the expression of ␤-adrenergic receptors is suppressed through enhanced noradrenergic stimulation. Thus, the anticatabolic effects of transgenic overexpression of mIgf-1 in vivo compensate for a reduced intrinsic stimulation of Akt signaling in skeletal in the setting of CLVD.
Foxo factor-mediated transcriptional activation has been associated with enhanced proteolysis and muscle atrophy. 20, 22 In mammals, the forkhead transcription factors include Foxo1 (FKHR), Foxo3 (FKHRL1), and Foxo4 (AFX). 22 Increased expression of Foxo1 occurs during muscle atrophy, 29 and phosphorylation of Foxo1, Foxo3, and Foxo4 leads to nuclear exclusion inhibiting their transcriptional activity. 20, 22 Overexpression of constitutively active Foxo enhances activity of the atrogin-1/MAFbx promoter and increases levels of atrogin-1/MAFbx mRNA, whereas gene silencing of Foxo1-Foxo3 through RNA interference blocks atrogin/MAFbx promoter activity. 22 In muscle cell cultures, expression of a dominant negative Akt molecule leads to robust induction of Foxo transcription factors and activation of a Foxo-dependent gene program, which is characteristic for muscle atrophy. 20 Overexpression of Akt in skeletal muscle 22 and heart 35 induces phosphorylation of Foxo transcription factors, suppresses the expression of Foxo-dependent atrogenes, and induces myocyte hypertrophy. In the present study, MLC/mIgf-1 expression elicited a robust phosphorylation of Foxo4 (AFX) which was induced in muscle of both sham and CLVD animals. Notably, the mIgf-1 transgene did not alter absolute Foxo protein levels and did not significantly affect the phosphorylation of Foxo1 or Foxo3. AFX is the most abundant forkhead transcription factor expressed in skeletal muscle, 36 and, therefore, its inactivation may afford particularly dramatic prevention of muscle wasting.
It has been demonstrated by several groups that the expression of atrogin-1/MAFbx in muscle atrophy is controlled by Foxo transcription factors, 20, 22 and activation of mTOR signaling has been implicated in myocyte hypertrophy in response to IGF-1 stimulation. 17 In agreement with these observations, stimulation of SOL8 myoblasts with IGF-1 protein led to an activation of the mTOR pathway with enhanced phosphorylation of mTOR and p70 s6k . Inhibition of this pathway by rapamycin reduced the effects of IGF-1 on levels of atrogin-1/MAFbx, indicating that this pathway participates in the regulation of atrogene expression. Notably, this has recently been confirmed by another group. 37 Interestingly, transgenic overexpression of mIgf-1 had only modest effects on activation of the mTOR pathway in vivo. Because phosphorylation of mTOR and p70 s6k are not altered in CLVD, we conclude that this pathway is not implicated in muscle atrophy in the setting of chronic heart failure. In contrast, CLVD induced significant changes in the Akt/Foxo pathway, suggesting its pivotal role in mechanisms of muscle atrophy. One might speculate that Akt/Foxo signaling regulates muscle atrophy, whereas mTOR activation is required for muscle hypertrophy. 38 The exact role of these pathways in mechanisms of muscle metabolism, however, requires further investigation.
Consideration of IGF-1 isoforms is critical in the interpretation of current studies on the effects of supplementary growth factors. Exogenously administered IGF-1 induces muscle hypertrophy through autocrine and paracrine mechanisms, 39 and muscle-specific overexpression of a circulating IGF-1 isoform results in profound muscle growth mediated through increased protein synthesis and DNA accretion. 40 Overexpression of the locally acting mIgf-1 isoform counters the decline in muscle mass in mdx mice, 41 in a mouse model of amyotrophic lateral sclerosis, 42 in senescence, 43 and in response to angiotensin II infusion. 28 Gene transfer of mIgf-1 under the control of muscle-specific regulatory elements prevents age-related loss of skeletal muscle mass and function, even when administered at senescence. 44 Additionally, mIGF-1 may act as a potent regenerative agent, as increased stem cell recruitment to sites of muscle injury was observed in mice expressing the MLC/mIgf-1 transgene. When isolated from MLC/mIgf-1 muscles, these progenitor cells exhibit accelerated myogenic differentiation and induce musclespecific markers in cocultured bone marrow cells. 44 From these and other analyses (N. Winn and N. Rosenthal, manuscript in preparation), it is likely that locally produced mIgf-1 counteracts atrophy through signaltransduction pathways that are distinct from those activated by circulating IGF-1.
